{"id":10424,"date":"2017-07-07T00:00:00","date_gmt":"2017-07-06T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2017\/07\/07\/nuevas-estrategias-epigenomicas-en-el-manejo-clinico-del-cancer-de-origen-desconocido\/"},"modified":"2020-05-19T18:49:44","modified_gmt":"2020-05-19T16:49:44","slug":"nuevas-estrategias-epigenomicas-en-el-manejo-clinico-del-cancer-de-origen-desconocido","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2017\/07\/nuevas-estrategias-epigenomicas-en-el-manejo-clinico-del-cancer-de-origen-desconocido\/","title":{"rendered":"Nuevas estrategias epigen\u00f3micas en el manejo cl\u00ednico del c\u00e1ncer de origen desconocido"},"content":{"rendered":"
La invenci\u00f3n del test epigen\u00e9tico EPICUP\u00ae ha permitido en el \u00faltimo a\u00f1o descubrir qu\u00e9 tipo de tumor primario ha producido la met\u00e1stasis en pacientes de C\u00e1ncer de Origen Desconocido (COD, o por sus siglas en ingl\u00e9s, CUP – Cancer of Unknown Primary). Hoy, un art\u00edculo publicado en Nature Reviews Clinical Oncology por Manel Esteller, coordinador del Programa de Epigen\u00e9tica y Biolog\u00eda del C\u00e1ncer del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), Investigador ICREA y Profesor de Gen\u00e9tica de la Universidad de Barcelona, \u200bexplica c\u00f3mo se est\u00e1 implantando esta prueba en la pr\u00e1ctica cl\u00ednica y los nuevos avances que se pueden derivar de la misma.
\u201cSolo en un 30% de casos de met\u00e1stasis de origen desconocido los m\u00e9todos tradicionales permiten detectar el tumor primario donde se ha originado. Algunos m\u00e9todos moleculares permiten aumentar este porcentaje, pero suelen ser caros y usan la mol\u00e9cula de ARN (\u00e1cido ribonucleico) que es muy fr\u00e1gil y suele romperse con facilidad en las muestras disponibles en los servicios de anatom\u00eda patol\u00f3gica de los hospitales.\u201d comenta el Dr. Manel Esteller.
\u201cEl test EPICUP\u00ae, en cambio, se basa en la mol\u00e9cula de ADN, que es muy estable, y permite el env\u00edo desde el hospital donde se encuentra el paciente hasta el laboratorio de an\u00e1lisis de forma sencilla. Los resultados se pueden obtener en una semana\u201d \u2013a\u00f1ade el investigador.
El C\u00e1ncer de Origen Desconocido (COD) representa el 10% de los tumores humanos en los que se detecta la met\u00e1stasis, pero no es posible localizar el tumor primario a pesar de realizarse distintas pruebas exploratorias. Como se desconoce de qu\u00e9 tipo de tumor se trata, la supervivencia de estos pacientes es muy corta; la implementaci\u00f3n del test EPICUP\u00ae permitir\u00e1 desarrollar tratamientos m\u00e1s espec\u00edficos en el futuro, de acuerdo con los resultados expuestos en Nature Reviews Clinical Oncology: \u201cAhora son necesarios ensayos prospectivos para determinar c\u00f3mo estos pacientes con CUP, ahora correctamente diagnosticados, se pueden beneficiar de tratamientos m\u00e1s especificos y menos agresivos para su enfermedad\u201d, concluye el Dr. Esteller.<\/p>\n","protected":false},"excerpt":{"rendered":"
La invenci\u00f3n del test epigen\u00e9tico EPICUP\u00ae ha permitido en el \u00faltimo a\u00f1o descubrir qu\u00e9 tipo de tumor primario ha producido la met\u00e1stasis en pacientes de C\u00e1ncer de Origen Desconocido (COD, o por sus siglas en ingl\u00e9s, CUP – Cancer of Unknown Primary). Hoy, un art\u00edculo publicado en Nature Reviews Clinical Oncology por Manel Esteller, coordinador […]<\/p>\n","protected":false},"author":6,"featured_media":10425,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[184,286],"tags":[],"class_list":["post-10424","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-area-cancer","category-epigenetica-del-cancer-cancer"],"publishpress_future_action":{"enabled":false,"date":"2025-05-02 22:54:41","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/10424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=10424"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/10424\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/10425"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=10424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=10424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=10424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}